Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease

Circulation. 2018 Oct 9;138(15):1599-1601. doi: 10.1161/CIRCULATIONAHA.118.033810.

Brian Claggett¹, John M Lachin², Stefan Hantel³, David Fitchett^{4

5}, Silvio E Inzucchi⁶, Hans J Woerle⁷, Jyothis T George⁷, Bernard Zinman^{5

8}

¹ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (B.C.).
² Biostatistics Center, George Washington University, Rockville, MD (J.M.L.).
³ Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.H.).
⁴ St. Michael's Hospital, Division of Cardiology (D.F.), Canada.
⁵ University of Toronto (D.F., B.Z.), Canada.
⁶ Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.).
⁷ Boehringer Ingelheim International GmbH, Germany (H.J.W., J.T.G.).
⁸ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada (B.Z.).

No abstract available

Keywords: cardiovascular diseases; diabetes mellitus; empagliflozin.

Publication types